Zoetis Inc. (ZTS) Free cash flow
- Free cash flow · 12 months (USD): Value $2.32B; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value 24.31%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $2.32B | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $2.84B − $524.00M ≈ $2.32B |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | 24.31% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $2.32B ÷ $9.53B × 100 ≈ 24.31% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $2.84B | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 1.08× | Operating cash flow / net income. Period ending 2026-06-30. $2.84B ÷ $2.64B ≈ 1.08× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | 2.84B USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 524.00M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | 2.32B USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 9.53B USD | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | 2.64B USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.32B | (m) | $2.84B | $524.00M | (m) | $9.53B | (m) | $2.64B | (m) | (m) | 24.31% | 1.08× |
| 2026-03-31 | $2.24B | (m) | $2.79B | $553.00M | (m) | $9.53B | (m) | $2.67B | (m) | (m) | 23.47% | 1.04× |
| 2025-12-31 | $2.28B | (m) | $2.90B | $621.00M | (m) | $9.47B | (m) | $2.67B | (m) | (m) | 24.12% | 1.09× |
| 2025-09-30 | $2.24B | (m) | $2.92B | $676.00M | (m) | $9.40B | (m) | $2.65B | (m) | (m) | 23.84% | 1.10× |
| 2025-06-30 | $2.22B | (m) | $2.93B | $710.00M | (m) | $9.38B | (m) | $2.61B | (m) | (m) | 23.64% | 1.12× |
| 2025-03-31 | $2.28B | (m) | $2.94B | $664.00M | (m) | $9.29B | (m) | $2.52B | (m) | (m) | 24.56% | 1.17× |
| 2024-12-31 | $2.30B | (m) | $2.95B | $655.00M | (m) | $9.26B | (m) | $2.49B | (m) | (m) | 24.83% | 1.19× |
| 2024-09-30 | $2.31B | (m) | $2.94B | $637.00M | (m) | $9.15B | (m) | $2.43B | (m) | (m) | 25.22% | 1.21× |
| 2024-06-30 | $2.10B | (m) | $2.72B | $615.00M | (m) | $8.91B | (m) | $2.34B | (m) | (m) | 23.59% | 1.16× |
| 2024-03-31 | $1.75B | (m) | $2.40B | $649.00M | (m) | $8.73B | (m) | $2.39B | (m) | (m) | 20.04% | 1.00× |
| 2023-12-31 | $1.62B | (m) | $2.35B | $732.00M | (m) | $8.54B | (m) | $2.34B | (m) | (m) | 18.97% | 1.00× |
| 2023-09-30 | $1.49B | (m) | $2.20B | $705.00M | (m) | $8.37B | (m) | $2.28B | (m) | (m) | 17.82% | 0.96× |
| 2023-06-30 | $1.28B | (m) | $2.00B | $714.00M | (m) | $8.22B | (m) | $2.21B | (m) | (m) | 15.63% | 0.90× |
| 2023-03-31 | $1.46B | (m) | $2.15B | $694.00M | (m) | $8.09B | (m) | $2.07B | (m) | (m) | 18.01% | 1.04× |
| 2022-12-31 | $1.33B | (m) | $1.91B | $586.00M | (m) | $8.08B | (m) | $2.11B | (m) | (m) | 16.41% | 0.90× |
| 2022-09-30 | $1.27B | (m) | $1.85B | $583.00M | (m) | $8.01B | (m) | $2.07B | (m) | (m) | 15.82% | 0.90× |
| 2022-06-30 | $1.43B | (m) | $1.98B | $548.00M | (m) | $8.00B | (m) | $2.09B | (m) | (m) | 17.87% | 0.95× |
| 2022-03-31 | $1.61B | (m) | $2.12B | $515.00M | (m) | $7.89B | (m) | $2.07B | (m) | (m) | 20.36% | 1.02× |
| 2021-12-31 | $1.74B | (m) | $2.21B | $477.00M | (m) | $7.78B | (m) | $2.04B | (m) | (m) | 22.33% | 1.09× |
| 2021-09-30 | $1.79B | (m) | $2.25B | $461.00M | (m) | $7.62B | (m) | $1.98B | (m) | (m) | 23.52% | 1.14× |
| 2021-06-30 | $1.70B | (m) | $2.16B | $459.00M | (m) | $7.41B | (m) | $1.91B | (m) | (m) | 22.96% | 1.13× |
| 2021-03-31 | $1.68B | (m) | $2.12B | $436.00M | (m) | $7.01B | (m) | $1.77B | (m) | (m) | 23.99% | 1.19× |
| 2020-12-31 | $1.67B | (m) | $2.13B | $453.00M | (m) | $6.67B | (m) | $1.64B | (m) | (m) | 25.06% | 1.30× |
| 2020-09-30 | $1.52B | (m) | $1.99B | $467.00M | (m) | $6.54B | (m) | $1.66B | (m) | (m) | 23.28% | 1.20× |
| 2020-06-30 | $1.46B | (m) | $1.93B | $478.00M | (m) | $6.34B | (m) | $1.62B | (m) | (m) | 22.97% | 1.20× |
| 2020-03-31 | $1.32B | (m) | $1.81B | $491.00M | (m) | $6.34B | (m) | $1.61B | (m) | (m) | 20.87% | 1.13× |
| 2019-12-31 | $1.33B | (m) | $1.79B | $460.00M | (m) | $6.26B | (m) | $1.50B | (m) | (m) | 21.33% | 1.20× |
| 2019-09-30 | $1.36B | (m) | $1.80B | $432.00M | (m) | $6.15B | (m) | $1.46B | (m) | (m) | 22.20% | 1.23× |
| 2019-06-30 | $1.46B | (m) | $1.84B | $378.00M | (m) | $6.05B | (m) | $1.38B | (m) | (m) | 24.20% | 1.34× |
| 2019-03-31 | $1.44B | (m) | $1.79B | $348.00M | (m) | $5.91B | (m) | $1.39B | (m) | (m) | 24.38% | 1.29× |
| 2018-12-31 | $1.45B | (m) | $1.79B | $338.00M | (m) | $5.83B | (m) | $1.43B | (m) | (m) | 24.93% | 1.25× |
| 2018-09-30 | $1.53B | (m) | $1.81B | $283.00M | (m) | $5.72B | (m) | $1.16B | (m) | (m) | 26.76% | 1.56× |
| 2018-06-30 | $1.45B | (m) | $1.70B | $257.00M | (m) | $5.59B | (m) | $1.11B | (m) | (m) | 25.88% | 1.53× |
| 2018-03-31 | $1.38B | (m) | $1.62B | $235.00M | (m) | $5.44B | (m) | $978.00M | (m) | (m) | 25.38% | 1.65× |
| 2017-12-31 | $1.12B | (m) | $1.35B | $224.00M | (m) | $5.31B | (m) | $864.00M | (m) | (m) | 21.14% | 1.56× |
| 2017-10-01 | $823.00M | (m) | $1.02B | $201.00M | (m) | $5.12B | (m) | $937.00M | (m) | (m) | 16.06% | 1.09× |
| 2017-07-02 | $614.00M | (m) | $824.00M | $210.00M | (m) | $5.02B | (m) | $878.00M | (m) | (m) | 12.24% | 0.94× |
| 2017-04-02 | $568.00M | (m) | $781.00M | $213.00M | (m) | $4.96B | (m) | $855.00M | (m) | (m) | 11.46% | 0.91× |
| 2016-12-31 | $497.00M | (m) | $713.00M | $216.00M | (m) | $4.89B | (m) | $821.00M | (m) | (m) | 10.17% | 0.87× |
| 2016-10-02 | $468.00M | (m) | $705.00M | $237.00M | (m) | $4.88B | (m) | $689.00M | (m) | (m) | 9.58% | 1.02× |
| 2016-07-03 | $438.00M | (m) | $670.00M | $232.00M | (m) | $4.86B | (m) | $639.00M | (m) | (m) | 9.02% | 1.05× |
| 2016-04-03 | $431.00M | (m) | $655.00M | $224.00M | (m) | $4.83B | (m) | $378.00M | (m) | (m) | 8.93% | 1.73× |
| 2015-12-31 | $440.00M | (m) | $664.00M | $224.00M | (m) | $4.76B | (m) | $339.00M | (m) | (m) | 9.23% | 1.96× |
| 2015-09-27 | $579.00M | (m) | $773.00M | $194.00M | (m) | $4.81B | (m) | $443.00M | (m) | (m) | 12.03% | 1.74× |
| 2015-06-28 | $488.00M | (m) | $672.00M | $184.00M | (m) | $4.81B | (m) | $420.00M | (m) | (m) | 10.15% | 1.60× |
| 2015-03-29 | $529.00M | (m) | $709.00M | $180.00M | (m) | $4.79B | (m) | $593.00M | (m) | (m) | 11.04% | 1.20× |
| 2014-12-31 | $446.00M | (m) | $626.00M | $180.00M | (m) | $4.79B | (m) | $583.00M | (m) | (m) | 9.32% | 1.07× |
| 2014-09-28 | $359.00M | (m) | $537.00M | $178.00M | (m) | $4.72B | (m) | $562.00M | (m) | (m) | 7.61% | 0.96× |
| 2014-06-29 | $357.00M | (m) | $548.00M | $191.00M | (m) | $4.61B | (m) | $527.00M | (m) | (m) | 7.74% | 1.04× |
| 2014-03-30 | $170.00M | (m) | $377.00M | $207.00M | (m) | $4.57B | (m) | $519.00M | (m) | (m) | 3.72% | 0.73× |
| 2013-12-31 | $497.00M | (m) | $681.00M | $184.00M | (m) | $4.56B | (m) | $504.00M | (m) | (m) | 10.90% | 1.35× |
| 2013-09-29 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $328.00M | (m) | $454.00M | $126.00M | (m) | $4.34B | (m) | $436.00M | (m) | (m) | 7.56% | 1.04× |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-07-01 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-04-01 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $362.00M | (m) | $497.00M | $135.00M | (m) | $4.23B | (m) | $245.00M | (m) | (m) | 8.55% | 2.03× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |